BeyondSpring Inc. announced that G. Kenneth Lloyd will retire from his role as Chief Scientific Officer of the Company, effective as of March 31, 2024. Effective immediately upon Dr. Lloyd?s retirement, June Lu will be appointed as the Company?s Chief Scientific Officer. Dr. Lu is an accomplished professional in scientific, translational, and strategic analysis aspects of R&D projects and pipeline assets, with nearly 25 years of industry experience in innovative drug research and development.

Dr. Lu joined the Company in October 2021 as Senior Director of Pre-Clinical and was recently promoted to Executive Director of Translational Medicine in July 2023. Prior to joining the Company, Dr. Lu held various Director positions with increasing responsibilities at Endocyte, Advanced Accelerator Applications, a Novartis company, and Novartis Institute for Biomedical Research. Dr. Lu received her Ph.D. in chemistry from Purdue University and B.S. degree in analytical chemistry from Zhejiang University of Technology.